Roll out of personalised CAR-T cancer therapies
Hundreds more people with cancer are now set to receive personalised CAR-T therapies. The immunotherapies, which use a patient’s own immune cells to create a tailored treatment, will immediately be made available through the Cancer Drugs Fund (CDF) for people with one of two forms of blood cancer. CAR-T, or chimeric antigen receptor T-cell therapy, involves reprogramming the patient’s own immune system and using immune cells to target their cancer.